{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:58:59Z","timestamp":1791125939414,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To examine cancer genes undergoing epigenetic inactivation in a set of T-cell acute lymphoblastic leukemias (T-ALLs) to obtain the CpG island methylator phenotype (CIMP) in the disease and its possible correlation with clinical features and outcome of the patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Methylation-specific polymerase chain reaction was used to analyze methylation of the ADAMTS-1, ADAMTS-5, APAF-1, ASPP-1, CDH1, CDH13, DAPK, DIABLO, DKK-3, LATS-1, LATS-2, NES-1, p14, p15, p16, p57, p73, PARK-2, PTEN, sFRP1\/2\/4\/5, SHP-1, SYK, TMS-1, and WIF-1 genes in samples from 50 consecutive T-ALL patients (19 children and 31 adults). Results were compared with results obtained in 286 B-cell acute lymphoblastic leukemias (B-ALLs). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A total of 88% of the T-ALL samples had at least one gene methylated. According to the number of methylated genes observed in each individual sample, 12 patients (24%) were included in the CIMP\u2212 group (zero to two methylated genes), and 38 patients (76%) were included in the CIMP+ group (&gt; two methylated genes). Clinical features and remission rate did not differ significantly among both groups of patients. Estimated disease-free survival (DFS) rate at 12 years and overall survival (OS) rate at 13 years were 100% and 91% for the CIMP\u2212 group and 20% and 17% for the CIMP+ group, respectively (P = .0006 and P = .003, respectively). Multivariate analysis demonstrated that methylation profile was an independent prognostic factor in predicting DFS (P = .05) and OS (P = .02). A group of five genes (SYK-1, ASPP-1, sFRP-2, sFRP-5, and WIF-1) showed specificity for T-ALL compared with B-ALL. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in T-ALL. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.01.4944","type":"journal-article","created":{"date-parts":[[2005,9,28]],"date-time":"2005-09-28T23:18:42Z","timestamp":1127949522000},"page":"7043-7049","source":"Crossref","is-referenced-by-count":114,"title":["Lack of CpG Island Methylator Phenotype Defines a Clinical Subtype of T-Cell Acute Lymphoblastic Leukemia Associated With Good Prognosis"],"prefix":"10.1200","volume":"23","author":[{"given":"Jose","family":"Roman-Gomez","sequence":"first","affiliation":[{"name":"From the Hematology Department, Reina Sofia Hospital, Cordoba; Hematology Department, Carlos Haya Hospital, Malaga; and Hematology Department, Cellular Therapy Area, Clinica Universitaria\/School of Medicine, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimenez-Velasco","sequence":"additional","affiliation":[{"name":"From the Hematology Department, Reina Sofia Hospital, Cordoba; Hematology Department, Carlos Haya Hospital, Malaga; and Hematology Department, Cellular Therapy Area, Clinica Universitaria\/School of Medicine, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Agirre","sequence":"additional","affiliation":[{"name":"From the Hematology Department, Reina Sofia Hospital, Cordoba; Hematology Department, Carlos Haya Hospital, Malaga; and Hematology Department, Cellular Therapy Area, Clinica Universitaria\/School of Medicine, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[{"name":"From the Hematology Department, Reina Sofia Hospital, Cordoba; Hematology Department, Carlos Haya Hospital, Malaga; and Hematology Department, Cellular Therapy Area, Clinica Universitaria\/School of Medicine, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Heiniger","sequence":"additional","affiliation":[{"name":"From the Hematology Department, Reina Sofia Hospital, Cordoba; Hematology Department, Carlos Haya Hospital, Malaga; and Hematology Department, Cellular Therapy Area, Clinica Universitaria\/School of Medicine, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Torres","sequence":"additional","affiliation":[{"name":"From the Hematology Department, Reina Sofia Hospital, Cordoba; Hematology Department, Carlos Haya Hospital, Malaga; and Hematology Department, Cellular Therapy Area, Clinica Universitaria\/School of Medicine, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907"},{"key":"R2","unstructured":"Uckun FM, Sensel MG, Sun L, et al: Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 91:735,1998-746,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401555"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.116"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1101\/gad.947102"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.4632"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023075"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0954"},{"key":"R9","unstructured":"Bene MC, Castoldi G, Knapp W, et al: Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9:1783,1995-1786,"},{"key":"R10","unstructured":"Ortega JJ: Spanish acute lymphoblastic leukemia trials. Int J Pediat Hemat Oncol 5:163,1998-176,"},{"key":"R11","unstructured":"Ribera JM, Ortega JJ, Oriol A, et al: Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 87:154,2002-166,"},{"key":"R12","unstructured":"Ribera JM, Ortega JJ, Oriol A, et al: Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia: Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Haematologica 83:222,1998-230,"},{"key":"R13","unstructured":"Ortega JJ, Ribera JM, Oriol A, et al: Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate-risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 Trial. Haematologica 86:586,2001-595,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206603"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602107"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20164"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.191"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1389"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207881"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206313"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0843-1"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.166"},{"key":"R23","unstructured":"Takeuchi S, Bartram CR, Wada M, et al: Allelotype analysis of childhood acute lymphoblastic leukemia. Cancer Res 55:5377,1995-5382,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9821"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401129"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15542-6"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3243"}],"updated-by":[{"DOI":"10.1200\/jco.2013.49.1290","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"record-id":"5498"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.01.4944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:39:56Z","timestamp":1653511196000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.01.4944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":27,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2005,10,1]]}},"alternative-id":["10.1200\/JCO.2005.01.4944"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.01.4944","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,1]]}}}